Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Payables (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Payables for 12 consecutive years, with $53.3 million as the latest value for Q4 2025.

  • Quarterly Payables rose 442.66% to $53.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.3 million through Dec 2025, up 442.66% year-over-year, with the annual reading at $53.3 million for FY2025, 442.66% up from the prior year.
  • Payables hit $53.3 million in Q4 2025 for Viking Therapeutics, up from $4.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $53.3 million in Q4 2025 to a low of $254000.0 in Q3 2024.
  • Historically, Payables has averaged $7.7 million across 5 years, with a median of $5.4 million in 2024.
  • Biggest five-year swings in Payables: crashed 95.55% in 2024 and later skyrocketed 1637.4% in 2025.
  • Year by year, Payables stood at $1.4 million in 2021, then surged by 490.65% to $8.5 million in 2022, then decreased by 11.92% to $7.5 million in 2023, then surged by 30.63% to $9.8 million in 2024, then surged by 442.66% to $53.3 million in 2025.
  • Business Quant data shows Payables for VKTX at $53.3 million in Q4 2025, $4.4 million in Q3 2025, and $5.5 million in Q2 2025.